MedTrace Logo

An In Vivo 24-Hour Recovery Study of Whole Blood by the Reveos System

NCT05239455 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2025-01-08

Study results available
· View outcomes & findings →

Summary

This is an in vivo 24-hour recovery study of leukoreduced red blood cells (RBCs) after automated separation of whole blood by the Reveos Automated Blood Processing System and storage for 42 days.

Conditions

  • Device Validation of In-vivo Performance

Interventions

DEVICE

Reveos® Automated Blood Processing System

This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from WB processed with the Reveos System.

Sponsors & Collaborators

  • Terumo BCT

    lead INDUSTRY

Principal Investigators

  • Jose A Cancelas, MD, PhD · Hoxworth Blood Center, University of Cincinnati

  • Moritz Stolla, MD, PhD · Bloodworks Northwest Research Institute

  • James Kelley, MD, PhD · Terumo BCT

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-11
Primary Completion
2022-04-30
Completion
2022-04-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05239455 on ClinicalTrials.gov